Large-Scale Engineering and Cryopreservation of hiPSC-Derived Nephron Sheets

Loes E. Wiersma (✉ l.e.wiersma@lumc.nl)  
Leiden University Medical Center

M. Cristina Avramut  
Leiden University Medical Center

Ellen Lievers  
Leiden University Medical Center

Ton J. Rabelink  
Leiden University Medical Center

Cathelijne W van den Berg  
Leiden University Medical Center

Research Article

Keywords: Induced Pluripotent Stem Cells, Kidney Organoids, Kidney Transplantation, Scale-up, Engineering, Cryopreservation, Regenerative Medicine, CRISPR

Posted Date: December 30th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1116352/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background The generation of human induced pluripotent stem cells (hiPSCs) has opened a world of opportunities for stem cell-based therapies in regenerative medicine. Currently, several human kidney organoid protocols are available that generate organoids containing kidney structures. However, these kidney organoids are relatively small ranging up to 0.13 cm\(^2\) and therefore contain a small number of nephrons compared to an adult kidney, thus defying the exploration of future use for therapy.

Method We have developed a scalable, easily accessible, and reproducible to increase the size of the organoid up to a nephron sheet of 2.5 cm\(^2\) up to a maximum of 12.6 cm\(^2\) containing a magnitude of nephrons.

Results Confocal microscopy showed that the subunits of the nephrons remain evenly distributed throughout the entire sheet and that these tissue sheets can attain ~30,000-40,000 glomerular structures. Upon transplantation in immunodeficient mice, such nephron sheets became vascularized and matured. They also show reuptake of injected low-molecular mass dextran molecules in the tubular structures, indicative of glomerular filtration. Furthermore, we developed a protocol for the cryopreservation of intermediate mesoderm cells during the differentiation and demonstrate that these cells can be successfully thawed and recovered to create such tissue sheets.

Conclusion The scalability of the procedures, and the ability to cryopreserve the cells during differentiation are important steps forward in the translation of these differentiation protocols to future clinical applications such as transplantable auxiliary kidney tissue.

Introduction

More than 10% of the world population suffers from chronic kidney disease[1] that can result in end-stage renal disease (ESRD) in which kidney function is lost. In 2030, an estimated 5.4 million people globally will have ESRD[2], fuelled by an aging population and increase in obesity, diabetes and cardiovascular disease[3]. To cope, ~5% of national healthcare budgets would need to be allocated to dialysis and expensive renal replacement therapies[4]. Kidney transplantation is currently the best clinical option but is hampered by organ availability and the use of immune suppressive drugs. These limitations drive the field of regenerative medicine to develop attractive therapies by engineering, replacing or regenerating cells, organs or tissues in order to restore function after damage or loss. The field has seen tremendous growth with the introduction of human induced pluripotent stem cells (hiPSC) [5] that can differentiate into any cell of the body. Generation of hiPSC-derived human kidney tissues may serve as an future alternative source of kidney tissue that could be used for transplantation purposes to (partially) restore kidney function[6]. In line, we previously demonstrated that transplanting hiPSC derived kidney organoids under the renal kidney capsule of immune deficient mice resulted in vascularisation, maturation, and functional and size selective glomerular filtration [7, 8].
However, to take this concept into further development towards clinical application, it is essential to demonstrate that the culture of these hiPSC-derived kidney organoids can be scaled to contain meaningful numbers of nephrons for such clinical application. Current dialysis treatment, on average, delivers 10% of the normal glomerular filtration and clearance. We therefore reasoned that a scaled culture system should be able to deliver at least 50,000 glomeruli to be considered as potential future auxiliary transplant tissue. Here we report a method to culture hiPSC-derived nephron tissue in sheets that contain tens of thousands of glomerular structures, while maintaining their ability to be transplanted and become functional. In addition, we show that the intermediate mesoderm cells in the differentiation culture can be cryopreserved thus enabling a structured and planned manufacturing process of these nephron sheets.

**Materials And Methods**

**hiPSC maintenance**

hiPSCs were maintained as previously described [7]. Briefly, all hiPSC lines were cultured in Essential 8 (E8) medium (Life Technologies) on vitronectin (Thermo Fisher Scientific) coated plates (Corning) and passaged twice a week with EDTA (Thermo Fisher Scientific). We used 3 hiPSC cell lines generated by the hiPSC core facility of the LUMC: LUMC0020iCTRL6.4, LUMC0072iCTRL01 and LUMC0099iCTRL04 that were generated from fibroblasts using Sendai virus [9], RNA (Simplicon RNA Reprogramming Kit, Millipore) and ReproRNA (Stemcell Technologies) respectively (detailed information at Human Pluripotent Stem Cell Registry, https://hpscreg.eu/). Additionally, we used reporter cell line MAFB:mTagBFP2 that was reprogrammed and gene-edited using CRISPR/Cas9 [10]. Cell lines are respectively referred to as LUMC0020, LUMC0072, LUMC0099 and iPSC-MAFB.

**Differentiation of organoids and nephron sheets**

Differentiation of organoids was described previously [7, 11]. Briefly, cells were seeded as single cells at variable densities (8,000 – 26,000 cells/cm²) per cell line on 6 well plates. Differentiating cells were dissociated on day 7 and centrifuged at 400xg containing 5 x 10⁵ cells per tube. Cell clumps were pipetted on top of a 0.4 µm pore transwell membrane (24 mm, Corning) and further maintained until day 7+18.

For differentiation to hiPSC-derived nephron sheets, hiPSCs were dissociated using TrypLE Select (Thermo Fisher Scientific) and plated at similar densities as above on a vitronectin coated T75 (Cellstar) in E8 medium supplemented with Revitacell. Differentiation was started the following day (day 0) by replacing medium with STEMdiff APEL2 Medium (APEL2, Stemcell Technologies) containing 1% PFHMII (Life Technologies), 1% Antibiotic-Antimycotic (Life Technologies) and 8 µM CHIR99021 (Tocris). On day 4 medium was switched to APEL2 supplemented with 200 ng/mL rhFGF9 (R&D Systems) and 1 µg/mL Heparin (Sigma-Aldrich). On day 7 intermediate mesodermal cells were dissociated after a 1 h pulse with 5 µM CHIR in APEL2 using Trypsin-EDTA (Thermo Fisher Scientific). Cells were counted using an
automated cell counter (NC-200) and centrifuged at 260xg in 50 mL tubes. Cells were seeded at a density between 19.5 – 23 x 10^6 cells/cm^2 on a 0.4 µm pore transwell (75 mm, Corning) using two different templates for cell distribution. Cells were plated either inside a rubber ring (DWK life science) or overlaid with a silicone cover (GRACE BIO-LABS). Nephron sheet differentiation was continued in APEL2 containing FGF9 and heparin with a media change every other day. On day 7+5 the template was removed from the sheet, and medium was changed to plain APEL2. Tissue sheets were maintained until day 7+18 before fixation with 2% PFA (Alfa Aesar) diluted in PBS.

**Cryopreservation of Differentiating Kidney Organoids**

Differentiating intermediate mesoderm cells from 4 independent differentiation experiments were cryopreserved on day 7. Cells were dissociated after CHIR pulse using Trypsin-EDTA, and single cells were counted and resuspended in ice-cold Nutrifreez (Biological Industries). Cryovials containing 8 x 10^6 cells/mL were rate controlled (-1°C/min) frozen to -80°C. 24 h later vials were transferred and stored in liquid nitrogen. For thawing, vials were warmed at 37°C and cells were transferred to a 50 mL tube containing plain DMEM and counted. Cells were centrifuged at the indicated density, resuspended in a small volume of 10% FBS in DMEM and pipetted onto the transwell membrane to allow tissue sheet formation using the templates. The protocol was continued as described above until day 7+18.

**Animal Experiments**

All animal experimental protocols were approved by the animal welfare committee of the Leiden University Medical Center and the Dutch Animal Experiments Committee. To allow for transplantation of nephron sheets, a hollow punch (Renssteig) was used to create a 2 mm circular biopsy. These biopsies were transplanted at day 7+17 under the renal capsule of both kidneys in 4 seven-week-old recipient mice (non-obese diabetic/severe combined immunodeficiency (NOD/SCID), Charles River Laboratories). Before sacrifice two mice were anesthetized with isoflurane and injected with low molecular mass 10 kDa dextran labelled with TetramethylRhodamine (TRITC, TdB Labs). Tissues were collected after 14 days of transplantation and processed for immunohistochemistry or transmission electron microscopy.

**Immunohistochemistry**

Organoids, untransplanted and transplanted nephron sheets were processed and stained as described previously [7]. In vitro organoids were fixed in 2% PFA for 20 min at 4°C before storage in PBS at 4°C. For further analysis biopsies of nephron sheets were either made with a blade or a hollow punch (3 mm, Renssteig). If required, tissues were embedded in TissueTek (Sakura) and stored at -80°C. Transplanted tissues were either immediately snapfrozen in Tissue Tek or fixed in 2% PFA overnight. Fixation of tissues containing fluorescent dextran was followed by 8 h incubation in 30% sucrose (Sigma) in PBS (B-BRAUN) at 4°C. Transplanted tissues were either stored in PBS or embedded in TissueTek. Tissue sections from embedded samples were made using a cryotome (5 – 10 µm thick).

For immunofluorescence analysis of in vitro organoids and nephron sheets (whole mount, biopsies or slides), samples were blocked in 10% Donkey Serum (Sigma-Aldrich) and 0.3% TritonX (Sigma Aldrich) in
PBS for 2 h at room temperature. Samples were stained with primary antibody in blocking buffer for 24 – 72 h at 4°C. For transplanted tissues Mouse on Mouse kit (MOM; Vector Laboratories) was used. Tissues were stained with primary antibodies for nephron structures: NPHS1 (R&D), NPHS2 (Abcam), ECAD (BD), LTL and DBA (Vector Laboratories), CUBN (Thermo Fisher Scientific and Abcam); endothelial cells: CD31 (BD) and MECA-32 (BD); and stromal cells: MEIS1/2/3 (Active Motif) and PDGFRα/β (Abcam). Samples were washed 3 times before adding secondary antibody mix for 2 h at room temperature (Supplemental Table 1). Nuclei were occasionally counterstained with Hoechst 33258. Organoids and biopsies from nephron sheets were mounted with ProLongGold (Thermo Fisher Scientific) in 35 mm glass bottom dish with a 14 mm or 22 mm glass diameter (MatTek corporation, Willco Wells), or 50 mm glass bottom dish with a 30 mm glass diameter (MatTek corporation). Our largest tissue sheet was mounted on a glass bottom plate (MatTek corporation). Nephron sheets were topped with 12, 20 or 55 mm coverslip, and left to dry for 24-48 h. Samples were imaged using a White Light Laser Confocal Microscope TCS SP8 (Leica) with LAS-X software 3.5.5 and an Andor Dragonfly Spinning Disk with Fusion 2.2 or higher software. LAS-X Image with 3D module and Imaris 9.5.0 were used to further analyze the data.

**Counting glomerular structures**

Organoids and biopsies of nephron sheets were stained for glomerular marker NPHS1 and nuclei with Hoechst. During confocal imaging Z-compensation for Excitation and Detector gain were used to create equal fluorescence intensity throughout the entire sample. NPHS1-positive structures were visualized using Imaris and further analyzed using the application ‘Surfaces’ to determine total volume and individual volume of glomerular structures (Supplemental Figure 1). The number of glomerular structures was calculated in individual images from independent experiments. This number was converted to number of glomerular structures in 3-dimensional organoids and nephron sheets.

**Transmission Electron Microscopy**

For Transmission Electron Microscopy (TEM) analysis, small biopsies of transplanted and non-transplanted nephron sheets were sampled and fixed for 1.5 h at room temperature in 1.5% glutaraldehyde (Electron Microscopy Sciences) in 0.1 M sodium cacodylate buffered solution, with pH 7.4. Samples were subsequently rinsed with sodium cacodylate buffer, fixed in 1% osmium tetroxide (Electron Microscopy Sciences) in 0.1 M sodium cacodylate buffer for 1 h on ice, then washed with sodium cacodylate buffer and dehydrated in a series of 70%, 80%, 90% and 100% ethanol. Next, samples were infiltrated with a mixture of 1:1 Epon LX-112 (Ladd Research) and propylene oxide (Electron Microscopy Sciences) for 1.5 h, followed by infiltration with pure Epon for 2 h. Afterwards, samples were mounted in BEEM capsules (Agar Scientific), embedded in pure Epon and polymerized for 48 h at 60°C. Ultrathin sections (100 nm) were collected on copper slot grids (Storck Veco BV), covered with formvar film and a 6 nm carbon layer. Sections were contrasted with an aqueous solution of 7% uranyl acetate for 20 min, followed by Reynolds's lead citrate for 10 min. Imaging was performed at an acceleration voltage of 120 kV on a FEI Tecnai G2 Spirit BioTWIN transmission electron microscope (FEI), equipped with an Eagle 4K slow-scan charge-coupled device camera (FEI). Large virtual slides of glomerular and tubular structures were acquired using automated large-scale data collection and stitching software [12] at
13,000x and 18,500x magnification. Aperio ImageScope software (Leica Biosystems) was used for the visualization of the virtual slides.

Results

Engineering hiPSC-derived nephron sheets using a template

The original differentiation protocol creates hiPSC-derived kidney organoids with glomerular, proximal tubular and distal tubular structures comparable to human kidney, but these tissues only range up to 4 mm in diameter (Figure 1A) [7, 11]. Here we focused on designing an easily accessible protocol to generate large hiPSC-derived nephron sheets and aimed to scale-up both the monolayer and 3-dimensional phase. The initial phase of monolayer culture was scaled up to a T75 cell culture flask with comparable seeding density as the original protocol.

Expansion of the 3-dimensional phase of differentiation was performed on a transwell membrane of 7.5 cm diameter. On these transwell membranes templates are necessary to enforce a restricted culture site for standardized seeding and reproducibility. We made use of 2 templates: a rubber ring with an inner circle of 18 mm and a silicone cover of 18 mm (Figure 1B and C). Both templates yielded similar nephron sheets that are indistinguishable by eye, structures observed in brightfield imaging and expression of kidney markers by immunofluorescence analysis (Figure 1D). We therefore combined results from both templates in this study. With these templates we created nephron sheets with a surface area of ~2.5 cm², while organoids only have a surface area of ~0.13 cm². After 5 days tissue sheets were firm enough to allow for the template to be removed. Sheets further developed in the same manner as the regular organoids. We explored the ability to generate large nephron sheets even further by using a 4 cm silicone cover (Figure 2). This allowed us to create a tissue sheet with a surface area of 12.6 cm² that showed similar characteristics as the 2.5 cm² as observed by eye and microscopy (Figure 2A).

Reproducible hiPSC-derived nephron sheets contain kidney structures

To investigate the presence of kidney structures in hiPSC-derived nephron sheets, samples were analyzed for glomerular structures (NHPS1 and NPHS2), endothelial cells (CD31), proximal tubules (LTL, CUBN), distal tubular structures (ECAD), and stromal cells (MEIS1/2/3 and PDGFRα/β) using confocal microscopy. Nephron sheet formation was reproducible in 4 different hiPSC lines (Figure 3A) and kidney structures were evenly distributed (Figure 3B, Supplemental Figure 2A-C). Our largest nephron sheet (12.6 cm²) also showed equal distribution of the kidney markers of interest (Figure 2B-E). Immunofluorescence analysis was compared to organoids and adult human kidney tissue slides (Supplemental Figure 3).

Assessment of hiPSC-derived nephron sheets and counting glomerular structures
Nephron sheet diameter was comparable in LUMC0072, LUMC0099 and iPSC-MAFB, while LUMC0020 yielded slightly smaller sheets (Figure 3C). We aimed to assess the number of glomerular structures (NPHS1+) in these tissue sheets and organoids from multiple independent experiments by using the size of individual glomerular structures and their distribution. The size of individual glomerular structures was determined by immunofluorescence analysis with Imaris. The sizes were comparable between cell lines and both types of organoids (Figure 3D). Total number of glomerular structures was evaluated and the average number of structures in organoids ranged between ~1,300 – 4,000 structures, and between ~30,000 – 40,000 in nephron sheets (Figure 3E).

**hiPSC-derived nephron sheets become vascularized and mature upon transplantation**

To evaluate whether nephron sheets vascularized and further matured upon transplantation, they were cultured until d7+17 and transplanted in mice. Due to space limitations under the renal capsule, we transplanted a biopsy of 2 mm of the tissue sheet. After two weeks, before sacrifice, 2 mice were intravenously injected with 10 kDa TRITC-labeled dextran. Confocal imaging showed the presence of all kidney structures and vascularization of the nephron sheet (Figure 4A). Furthermore, TRITC-labeled dextran was observed in glomerular structures demonstrating vascular connection with the host and in the tubular structures indicating functional filtration in glomerular structures (Figure 4B). Additionally, TEM-images of the transplanted organoids revealed endothelial cells and erythrocytes in the glomerular structures and maturation was further shown by the presence of fenestrae, open blood vessels, development of the glomerular basement membrane, and foot processes. Tubular structures had an open lumen, a single layer of epithelial cells, mitochondria, a brush border with microvilli, and displayed basal migration of the nuclei (Figure 4C). Glomerular structures in untransplanted nephron sheets showed formation of Bowman's space and centered glomerular basement membrane anticipating vascularization. The tubular structures showed open and closed lumens but were more disorganized than their transplanted counterparts (Supplemental Figure 4).

**hiPSC-derived nephron sheets can be cryopreserved during differentiation**

To explore if nephron sheets could be cryopreserved during differentiation, we froze cells at day 7 of differentiation (intermediate mesoderm phase) in cGMP-manufactured cryopreservation medium (Figure 5A). Nutrifreez provided excellent recovery and tissue sheets were able to continue differentiation after cryopreservation (Figure 5B, Supplemental Figure 5). Non-frozen and thawed sheets were compared under identical experimental conditions and immunofluorescence showed the presence of glomerular, proximal and distal tubular structures and endothelial cells (Figure 5C).

**Discussion**
Here we engineered a reproducible, scalable hiPSC-derived nephron sheet that can be easily implemented, and show that cryopreservation during differentiation allows for storage of intermediate mesoderm cells, containing progenitors of the kidney. These tissue sheets showed presence and even distribution of kidney structures, high number of glomerular like structures, and vascularization and maturation upon transplantation under the renal capsule in mice. As observed in previous transplantation studies [8, 13], filtration in glomerular structures was demonstrated by presence of low molecular mass dextran molecules in tubular structures.

Currently multiple protocols are available for designing iPSC-derived cell or tissue sheets, such as retinal pigment epithelium cells on collagen I, smooth muscle like cells on degradable hydrogel, and various cell types on temperature responsive cell culture surfaces like cardiac tissue and hepatocyte-like cells [14–17]. Some methods yield a single sheet layer, while others are stacked to create a multi-layered sheets [18, 19]. Lawlor et al. explored the use of a bioprinter to generate hiPSC-derived kidney organoids [20]. Their printed organoid patch (6 x 8 mm) consisted of a 3-dimensional layer. Our protocol does not require a bioprinter and it is designed to combine manual pipetting and a template to guide nephron sheet growth and patterning. The template creates an optimal ‘cell to square surface’ ratio of differentiating cells resulting in a 3-dimensional sheet. Without a pre-defined culture area, cell density is suboptimal, resulting in an uneven and poor differentiation. Nephron sheets made by either template showed minimal differences in distribution of structures. The templates are easy to use and can be removed without damaging the sheet, allowing further development of the tissue sheet. These nephron sheets can easily be moved from the transwell filter and are strong enough to be transferred without breaking. Additionally, it is important to note that shape and size can be adapted, at least up to 12.6 cm². For clinical purposes, designing an industrialized process for tissue sheet culture could include automated hiPSC-maintenance and differentiation during the monolayer phase, for example in a bioreactor or a multi-layered flask. After harvesting, cells could be further differentiated or cryopreserved. A combination of multiple systems combining hiPSC culture and nephron sheet differentiation could result in an engineered nephron sheet platform.

At present the only treatment for reduced kidney function is dialysis and kidney transplantation. These tissue sheets could potentially fill a gap that alleviates or delays the need for such therapy. We also counted glomerular structures in the tissue sheets as an indication for the amount of nephrons that can be transplanted. We found that the average sheets made with an 18 mm template gave rise to tens of thousands of structures, compared to one tenth of these structures in organoids. The latter deviates from previous findings [11] where 500 structures were counted in organoids. Takasato et al. counted structures manually in a 2D image while our method relies on 3D-imaging techniques using the total volume of structures providing a more accurate indication of the number of glomerular structures. With these numbers of glomerular structures in nephron sheets, we hypothesize that transplanting multiple sheets could potentially partially restore kidney function in patients.

To further apply these cultures for research and clinical applications, cryopreservation of differentiating cells is of great interest. We show efficient cryopreservation of differentiating kidney cells which alleviates
the need for continuous hiPSCs culture and differentiation, and gives rise to an accessible stock of cells. Cryopreservation will also allow for quality control screening on each batch of differentiating organoids. We show that nephron sheets displayed no difference in brightfield imaging and presence of kidney structures upon cryopreservation compared to continuously cultured sheets. Similarly, Mae et al. cryopreserved progenitors of induced ureteric bud organoids and found that they had the same potential to form nephric ducts epithelial aggregates as those who were not cryopreserved [21]. Other groups have shown that cryopreservation of hiPSC-derived cardiomyocytes and hiPSC-blood brain barrier microvascular endothelial cells had little to no adverse effect compared to differentiated cells that did not undergo cryopreservation [22, 23]. These and our findings show great promise for the use of cryopreservation and applicability of these differentiated cells. An additional advantage of the cryopreservation medium used in this study is that it is manufactured under cGMP conditions and allows for clinical translation to a GMP-compliant manufacturing protocol.

**Conclusion**

We have focused on developing an easily accessible, robust and efficient culture and cryopreservation method for creating large scale nephron sheets of high quality. These results constitute an important step to future application of these sheets as auxiliary tissue in the treatment of kidney disease in patients. While substantial challenges remain for safety, quality control and correct patterning of these structures, our findings are an advancement in the field of regenerative medicine.

**Abbreviations**

| Abbreviation | Definition                      |
|--------------|---------------------------------|
| CUBN         | Cubilin                         |
| DBA          | Dolichos biflorus agglutinin    |
| E8           | Essential 8                     |
| ECAD         | E-cadherin                      |
| ESRD         | End Stage Renal Disease         |
| hiPSC        | human induced Pluripotent Stem Cells |
| kDa          | kilodalton                      |
| LTL          | Lotus Tetragonolobus Lectin     |
| MOM          | Mouse on Mouse kit              |
| NPHS1        | Nephrin 1                       |
| NPHS2        | Podocin                         |
NOD/SCID  non-obese diabetic/severe combined immunodeciency
PDGFR  Platelet-derived growth factor
TEM  Transmission Electron Microscopy
TRITC  Tetramethylrhodamine

Declarations

Availability of data and materials

No datasets were generated or analyzed during the current study.

Acknowledgements

We thank Christian Freund (hiPSC core facility, LUMC, Leiden, the Netherlands) for providing three hiPSC lines (LUMC0072iCTRL01, LUMC0099iCTRL04 and LUMC0020iCTRL6.4), and Sara Howden and Melissa Little (Murdoch Children's Research Institute, Melbourne, Australia) for iPSC-MAFB. We acknowledge the support of Wendy Sol and Manon Zuurmond (LUMC, Leiden, the Netherlands). We thank the Light and Electron Microscopy Facility (LUMC) for assistance and maintenance of the microscopes. This work is supported by the partners of Regenerative Medicine Crossing Borders and Health Holland, Top Sector Life Sciences & Health. C.W. van den Berg is supported by the Wiyadharma Fellowship (Bontius stichting-LUMC).

Funding

Financial support is acknowledged from REGMED XB and the Wiyadharma Fellowship.

Author information

Affiliations

Department of Internal Medicine - Nephrology, Leiden University Medical Center, Leiden, The Netherlands
L.E. Wiersma, E. Lievers, T.J. Rabelink and C.W. van den Berg

Eindhoven Laboratory of Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands
L.E. Wiersma, E. Lievers, T.J. Rabelink and C.W. van den Berg

Department of Cell and Chemical Biology - Electron Microscopy, Leiden University Medical Center, Leiden, The Netherlands
M.C. Avramut
Author contributions

L.E. Wiersma: conception and design, collection and assembly of data, manuscript writing

M.C. Avramut: electron microscopy imaging

E. Lievers: technical support in vitro and in vivo experiments

T.J. Rabelink: responsible for funding, data analysis and interpretation, manuscript writing, final approval of manuscript

C.W. van den Berg: conception and design, collection and assembly of data, manuscript writing, final approval of manuscript

Corresponding author

Cathelijne W. van den Berg, PhD

Ethics declarations

Ethics approval and consent to participate

Ethics approval was provided by the animal welfare committee of the Leiden University Medical Center and the Dutch Animal Experiments Committee.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests

References

1. Chronic Kidney Disease Collaboration G.B.D. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020;395(10225):709-733, doi:https://doi.org/10.1016/S0140-6736(20)30045-3.

2. Liyanage T., Ninomiya T., Jha V. et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015;385(9981):1975–1982, doi:https://doi.org/10.1016/S0140-6736(14)61601-9.

3. Thurlow J.S., Joshi M., Yan G. et al. Global Epidemiology of End-Stage Kidney Disease and Disparities in Kidney Replacement Therapy. Am J Nephrol 2021;52(2):98–107, doi:https://doi.org/10.1159/000514550.
4. Himmelfarb J., Vanholder R., Mehrotra R. et al. The current and future landscape of dialysis. Nat Rev Nephrol 2020;16(10):573–585, doi:https://doi.org/10.1038/s41581-020-0315-4.

5. Takahashi K., Tanabe K., Ohnuki M. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131(5):861–872, doi:https://doi.org/10.1016/j.cell.2007.11.019.

6. Naganuma H., Nishinakamura R. From organoids to transplantable artificial kidneys. Transpl Int 2019;32(6):563–570, doi:https://doi.org/10.1111/tri.13404.

7. van den Berg C.W., Ritsma L., Avramut M.C. et al. Renal Subcapsular Transplantation of PSC-Derived Kidney Organoids Induces Neo-vasculogenesis and Significant Glomerular and Tubular Maturation In Vivo. Stem Cell Reports 2018;10(3):751–765, doi:https://doi.org/10.1016/j.stemcr.2018.01.041.

8. van den Berg C.W., Koudijs A., Ritsma L. et al. In Vivo Assessment of Size-Selective Glomerular Sieving in Transplanted Human Induced Pluripotent Stem Cell-Derived Kidney Organoids. J Am Soc Nephrol 2020;31(5):921–929, doi:https://doi.org/10.1681/ASN.2019060573.

9. Nishimura K., Sano M., Ohtaka M. et al. Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming. J Biol Chem 2011;286(6):4760–4771, doi:https://doi.org/10.1074/jbc.M110.183780.

10. Howden S.E., Thomson J.A., Little M.H. Simultaneous reprogramming and gene editing of human fibroblasts. Nat Protoc 2018;13(5):875–898, doi:https://doi.org/10.1038/nprot.2018.007.

11. Takasato M., Er P., Chiu H. et al. Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature 2015;526.

12. Faas F.G., Avramut M.C., van den Berg B.M. et al. Virtual nanoscopy: generation of ultra-large high resolution electron microscopy maps. J Cell Biol 2012;198(3):457–469, doi:https://doi.org/10.1083/jcb.201201140.

13. Bantounas I., Ranjzad P., Tengku F. et al. Generation of Functioning Nephrons by Implanting Human Pluripotent Stem Cell-Derived Kidney Progenitors. Stem Cell Reports 2018;10(3):766–779, doi:https://doi.org/10.1016/j.stemcr.2018.01.008.

14. Kamao H M.M., Okamoto S, Sakai N, Suga A, Sugita S, Kiryu J, Takahashi M. characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem cell reports 2014;2:205–2018, doi:https://doi.org/10.1016/j.stemcr.2013.12.007.

15. Kwong G., Marquez H.A., Yang C. et al. Generation of a Purified iPSC-Derived Smooth Muscle-like Population for Cell Sheet Engineering. Stem Cell Reports 2019;13(3):499–514, doi:https://doi.org/10.1016/j.stemcr.2019.07.014.

16. Ishigami M., Masumoto H., Ikuno T. et al. Human iPS cell-derived cardiac tissue sheets for functional restoration of infarcted porcine hearts. PLoS One 2018;13(8):e0201650, doi:https://doi.org/10.1371/journal.pone.0201650.

17. Nagamoto Y., Takayama K., Ohashi K. et al. Transplantation of a human iPSC-derived hepatocyte sheet increases survival in mice with acute liver failure. J Hepatol 2016;64(5):1068–1075, doi:https://doi.org/10.1016/j.jhep.2016.01.004.
18. Yang J., Yamato M., Kohno C. et al. Cell sheet engineering: recreating tissues without biodegradable scaffolds. Biomaterials 2005;26(33):6415–6422, doi:https://doi.org/10.1016/j.biomaterials.2005.04.061.

19. Raju R., Oshima M., Inoue M. et al. Three-dimensional periodontal tissue regeneration using a bone-ligament complex cell sheet. Sci Rep 2020;10(1):1656, doi:https://doi.org/10.1038/s41598-020-58222-0.

20. Lawlor K.T., Vanslambrouck J.M., Higgins J.W. et al. Cellular extrusion bioprinting improves kidney organoid reproducibility and conformation. Nat Mater 2020 doi:https://doi.org/10.1038/s41563-020-00853-9.

21. Mae S.I., Ryosaka M., Sakamoto S. et al. Expansion of Human iPSC-Derived Ureteric Bud Organoids with Repeated Branching Potential. Cell Rep 2020;32(4):107963, doi:https://doi.org/10.1016/j.celrep.2020.107963.

22. van den Brink L., Brandao K.O., Yangou L. et al. Cryopreservation of human pluripotent stem cell-derived cardiomyocytes is not detrimental to their molecular and functional properties. Stem Cell Res 2020;43:101698, doi:https://doi.org/10.1016/j.scr.2019.101698.

23. Linville R.M., DeStefano J.G., Nerenberg R.F. et al. Long-Term Cryopreservation Preserves Blood-Brain Barrier Phenotype of iPSC-Derived Brain Microvascular Endothelial Cells and Three-Dimensional Microvessels. Mol Pharm 2020;17(9):3425–3434, doi:https://doi.org/10.1021/acs.molpharmaceut.0c00484.

Figures

Figure 1

Generating hiPSC-derived nephron sheets using a template

A. Schematic of the protocol for generating hiPSC-derived kidney organoids. hiPSCs are cultured on multiwell plates as a monolayer until day 7. Cells are dissociated and pipetted as clumps on transwell membranes and cultured until day 7+18 (4 mm diameter and 0.13 cm² surface area).

B, C. Schematic of the protocol for generating hiPSC-derived nephron sheets. hiPSCs are differentiated in T75-culture flasks as a monolayer, followed by dissociation to single cells on day 7. Differentiated cells are either pipetted inside a ring (C, top) or pipetted cells are overlaid with a cover (C, bottom). Nephron sheets are cultured until day 7+18 and reach 18 mm diameter with 2.5 cm² surface area.
Scalebar inset: 5 mm

D. Images of whole tissue sheet (left) and brightfield (middle), and immunofluorescence (right) of nephron sheets generated with a ring (top) or cover (bottom).

Figure 2

Upscaling of nephron sheets to a diameter of at least 4 cm

A. Image of large-scale nephron sheet of 12.6 cm² made with a 4 cm diameter cover template (iPSC-MAFB)

B,C. Immunofluorescence analysis of the entire nephron sheet shows presence and equal distribution of kidney tubular structures stained for proximal (LTL, B) and distal (ECAD, C) markers

D. Section of the large nephron sheet highlights the distribution of tubular structures stained for LTL and ECAD combined.

E. Detection of nephron structures after immunofluorescence staining for glomerular structures (NPHS1), proximal tubules (LTL), and distal tubules (ECAD).

Figure 3

hiPSC-derived nephron sheets reproducibly contain kidney structures and show high number of glomerular structures

A. Immunofluorescence analysis for glomerular structures (NPHS1, NPHS2), endothelium (CD31), proximal tubule (LTL, CUBN), distal tubular and collecting duct structures (ECAD) in whole mount nephron sheets, and stromal cells (MEIS1/2/3, PDGFRα/β) in cryosections using LUMC0072, LUMC0099, LUMC0020 and iPSC-MAFB (representative images from 3 independent experiments).

B. Immunofluorescent 3-dimensional overview showing distribution of NPHS1, CD31 and LTL in bisected hiPSC-derived nephron sheet.

C. Diameter of hiPSC-derived nephron sheets using an 18 mm template in multiple hiPSC lines. (Independent experiments; n=11 (32 org) LUMC0072, n=2 (6 org) LUMC0099, n=3 (5 org) LUMC0020, n=6 (11 org) iPSC-MAFB).

D, E. Volume of glomerular structures (µm³) (D) and number of glomerular structures (E) of organoids and nephron sheets. (Independent experiments: organoid n=4 LUMC0072, n=2 LUMC0099, n=5
Figure 4

hiPSC-derived nephron sheet become vascularized and mature upon transplantation

iPSC-derived nephron sheet (LUMC0072) was differentiated in vitro until day 7+17 and biopsies were transplanted under renal capsule of immunocompromised mice. Tissues were collected after 2 weeks of transplantation.

A. Immunofluorescence analysis of cryosections demonstrates presence of glomerular structures (NPHS1, NPHS2), mouse endothelial cells (MECA-32), proximal tubules (LTL, CUBN), distal tubules and collecting duct (ECAD, DBA), and stromal cells (MEIS 1/2/3, PDGFRα/β).

B. Detection of intravenously injected low molecular mass dextran (10 kDa, TRITC labeled) combined with immunofluorescence analysis of glomerular (NPHS1) and proximal tubular (CUBN and LTL) on cryosections demonstrates functional filtration.

C. Transmission electron micrographs of a glomerular structure and proximal tubule after transplantation. The glomerular structure shows development of a Bowman's capsule and podocyte orientation towards a capillary (left image), erythrocytes and fenestrae are lining the blood vessel wall (top small image), smoothing of the glomerular basement membrane and endothelial cells are observed (middle small image) and tight junctions connect podocytes (bottom small image). Proximal tubule shows a single layer of epithelial cells, basal orientation of nuclei, mitochondria, and displays brush border with microvilli.

P, podocytes; BS, Bowman's space; PC, parietal cells; ER, erythrocytes; F, fenestrae; TJ, tight junctions; EC, endothelial cell; GBM, glomerular basement membrane; MV, microvilli; N, nuclei; M, mitochondria.

Figure 5

Cryopreservation of hiPSC-derived nephron sheets

A. Schematic of cryopreservation procedure. hiPSCs are differentiated until day 7 of differentiation, dissociated to single cells and cryopreserved. Cells are thawed and differentiation can be continued using both templates for hiPSC-derived nephron sheets.

B. Brightfield images of nephron sheets without (control) and with cryopreservation (representative image of 4 independent experiments).
Immunofluorescence analysis of glomerular structures (NPHS1, NPHS2), endothelium (CD31), proximal tubules (LTL, CUBN), distal tubular structures (ECAD) in whole mount control and cryopreserved nephron sheets (4 independent experiments).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- 20211125Wiersmaetal.SupplementalTable1.docx
- L.E.WiersmaSupplementalFigure1.tif
- L.E.WiersmaSupplementalFigure2.tif
- L.E.WiersmaSupplementalFigure3.tif
- L.E.WiersmaSupplementalFigure4.tif
- L.E.WiersmaSupplementalFigure5.tif